相关实验视频
Updated: May 24, 2025
13:25
Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
5.6K
卡维迪醇和西米蒂丁都通过降低OCT2的调节来减轻西斯普拉丁诱导的毒性
Huan Wu1, Yichun Ning2, Zhaoxing Sun1
1Department of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China; Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai, China.
概括
卡维迪醇和西米提丁通过抑制OCT2.2来预防西斯类药物引起的急性损伤 (Cis-AKI). 这些药物可以减少脏损伤,而不会影响西斯的抗瘤功效.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 西斯普拉丁化疗导致严重的毒性,限制了其使用.
- 有机阴离子转运体2 (OCT2) 在脏吸收思普拉丁中起作用.
- 缺乏有效的药理疗法,用于治疗西斯普拉丁诱导的急性损伤 (Cis-AKI).
研究的目的:
- 通过抑制OCT2.2,确定可以预防Cis-AKI的现有药物.
- 评估候选药物对细胞和体内模型的保护作用.
- 评估这些药物是否能够保持思丁的抗瘤活性.
主要方法:
- 在患者衍生细胞和器官中检查了OCT2mRNA水平.
- 对OCT2抑制和Cis-AKI保护作用进行选的FDA批准的药物.
- 评估药物对细胞和动物模型中OCT2表达,青吸收,亡和抗瘤活性的影响.
主要成果:
- 在Cis-AKI患者细胞中观察到高OCT2mRNA水平.
- 过度表达OCT2恶化了西斯普拉丁诱导的损伤.
- 卡维迪洛和西米提丁被确定为强大的OCT2抑制剂.
- 这些药物降低了细胞中西斯丁的吸收和亡,而不会影响抗瘤作用.
结论:
- 卡维迪醇和丁丁通过OCT2抑制显示出对Cis-AKI的保护作用.
- 这些药物提供了一种潜在的策略,以减轻西斯的毒性.
- 这些已识别的药物维持了思丁对癌细胞的疗效.
相关概念视频
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
171
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
171
01:15Drug Elimination by Renal Route: Tubular Secretion
2.1K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.1K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
01:28Renal Drug Excretion: Tubular Secretion
104
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
104
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
363
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363